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Abstract
We aimed to determine which children are prone to non-Escherichia coli coli UTIs. We included 
769 children with UTI. We found that circumcised males, Hispanic children, children without 
fever, and children with Grade 3–4 VUR were more likely to have a UTI caused by organisms 
other than E. coli. This information may guide clinicians in their choice of antimicrobial therapy.
Keywords
Vesicoureteral reflux; Escherichia coli
BACKGROUND
The vast majority of cases of community-acquired urinary tract infection (UTI) are caused 
by E. coli. It may be clinically important to predict which children have UTIs caused by 
organisms other than E. coli because these organisms differ in their patterns of antimicrobial 
susceptibility. A recent study found that the organisms other that E. coli were less likely to 
be susceptible to first generation cephalosporins and nitrofurantoin.1 Furthermore, some 
guidelines2 have suggested that screening for vesicoureteral reflux (VUR) with a voiding 
cystourethrogram (VCUG) should, at least in part, be based on whether an organism other 
than E. coli is recovered.
Our objectives were (1) to determine clinical characteristics that might be useful in 
differentiating children with UTI caused by E. coli from children with UTIs caused by 
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organisms other than E. coli, and (2) to understand associations between clinical 
characteristics, VUR and pathogen type.
Methods
We used data from two prospective, multicenter studies, in which clinical and demographic 
characteristics were carefully documented, to determine characteristics associated with the 
type of infecting organism. The Randomized Intervention for Children with Vesicoureteral 
Reflux (RIVUR) trial included 607 children with VUR and the parallel observational 
Careful Urinary Tract Infection Evaluation (CUTIE) study enrolled 195 children without 
VUR. We excluded 33 children with missing data (for organism, voiding cystourethrogram, 
race, ethnicity, antibiotic treatment, or presence of bladder and bowel dysfunction [BBD]), 
with a resulting analytic sample of 769 children. Methods of the RIVUR and CUTIE studies 
have been previously reported.3–5 Briefly, the RIVUR trial enrolled children 2 to 71 months 
of age presenting with a first or second febrile or symptomatic UTI from both primary and 
subspecialty care settings at clinical trial centers throughout North America. Children who 
were found to have grades I to IV VUR after their index UTI were enrolled in the RIVUR 
trial. Children 2 to 71 months of age with a first or second UTI but without VUR were 
enrolled in the CUTIE study at 3 of the 19 participating RIVUR sites (Pittsburgh, 
Philadelphia and Washington, DC). In both studies urine samples were collected by 
catheterization, suprapubic aspiration or by clean void; bag-collected specimens were not 
permitted.
We used logistic regression models to test the associations between demographic and 
clinical characteristics and uropathogen. The clinical model included baseline predictors 
known or easily measured at a clinical visit: age, gender, race, ethnicity, presence of BBD, 
use of antimicrobials in the preceding 6 months for infections other than UTIs, number of 
previous UTIs, type of index UTI (febrile vs. afebrile). We included site (grouped into 6 
administrative sites) in the model as a covariate, and categorized age as 2–11 months, 12–23 
months, 24–35 months, and 36–72 months. In the association model, we added VUR (a 
characteristic not known without performance of VCUG) to the clinical model. We also 
considered unadjusted associations with uropathogens for the following symptoms: 
suprapubic/abdominal/flank pain or tenderness, urinary urgency, urinary frequency, urinary 
hesitancy, dysuria, and foul-smelling urine.
Results
Of 769 children included, 703 (91%) were female and 596 (78%) were white. Forty-nine 
percent of the cohort was 2–11 months of age; 699 (91%) had index UTIs caused by E. coli. 
The 70 children with UTIs caused by organisms other than E. coli incuded 21 (30%) with 
Proteus species, 16 (23%) with Klebsiella species, 14 (20%) with Enterococcus species, 8 
(11%) with Enterobacter species, and 11 with other species. Data regarding the antimicrobial 
resistance of the organisms isolated from these children have been previously reported.1 
Children enrolled in the CUTIE study were older (30% vs. 20% were 36–72 months of age), 
more likely to be non-white (33% vs. 19%) and Hispanic (20% vs. 12%). Further details 
regarding the demographic makeup of the sample have previously been reported.
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In the clinical model, circumcised males (OR=5.5, 95% CI=1.8—17.1, p=0.003, Table) and 
Hispanic children (OR=2.3, 95% CI=1.1—4.6, p=0.02) were more likely to have infection 
caused by pathogens other than E. coli compared with females and non-Hispanic children, 
respectively (Table). Children without fever were also more likely to have infections caused 
by organisms other than E. coli (OR=2.8, 95% CI=1.2—6.6, p=0.02). Pathogen type was 
similar with respect to age, race, presence of BBD, duration of UTI symptoms before 
presentation, number of previous UTIs, and number of courses of antimicrobials received in 
the preceding 6 months for conditions other than UTI.
In the association model, children with grade 3–4 VUR had higher odds of non-E.coli 
infections (OR=2.2, 95% CI=1.2—4.1, p=0.01) compared with children with grade 1–2 
VUR (Table). Children with no VUR had a similar odds of non-E.coli infections compared 
to children with grade 1–2 VUR. In the association model, odds ratios noted in the clinical 
model were largely unchanged. Children 4 months or younger with failure to thrive had a 
higher percentage of non-E.coli infections than other children 4 months or younger (24% vs. 
11%). Primary pathogens were similar for other individual symptoms.
Discussion
We found that circumcised males, children with grade III or IV VUR, Hispanic children and 
children without fever were more likely to have UTI caused by organisms other than E. coli. 
The association between gender and organism type has been previously reported.6,7 Previous 
studies have also reported the association between VUR and uropathogen.8,9 High-grade 
VUR may be necessary for generally less virulent organisms, which lack adhesins prevalent 
among E. coli starins, to ascend to the kidney. The association between Hispanic ethnicity 
and non-E. coli pathogens is novel and may be due to differences in genes involved with 
susceptibility to UTIs. Fever with infections caused by E. coli may be related to the 
organism’s enhanced ability to ascend into the kidney.
Approximately one quarter of circumcised males and one quarter of afebrile children had 
infections caused by organisms other than E. coli. As a group, non-E. coli species are more 
likely to be resistant to first generation cephalosporins and nitrofurantoin.1 Accordingly, if 
these data are replicated, clinicians may want to avoid using first-line agents for the 
treatment of UTIs in these subgroups.; second or third generation cephalosporins would be 
the preferred agents.
Children with UTIs caused by organisms other than E. coli were twice as likely to have 
high-grade VUR (Grade III and IV), which is consistent with prior studies.8,9
The main limitation of this study is that the children we included are not likely 
representative of all children with UTI because tbecause a relatively large proportion of 
children had VUR. Nevertheless, after adjusting for VUR, circumcised males and afebrile 
children had higher rates of infection by organisms other than E. coli.
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